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Cdc42.4,5 In our study, the doubly lipidated R186C Cdc42 mutant
was retained in the Golgi (see Fig E4,B). This impaired its plasma
membrane anchoring and resulted in actin polymerization defects
and hyperactivation of NF-kB signaling.
In conclusion, our study identifies a strong link between
impaired cytosol/membrane cycling of Cdc42 resulting from
abnormal double lipidation, partial defects in actin polymeriza-
tion, and hyperactivation of NF-kB signaling, which can explain
the pathophysiology of the disease. More broadly, our findings
are consistent with reports in the literature that link inflamma-
tion with actin turnover6 and membrane targeting of Rho
GTPases.7-9 Thus, further investigation of the various conse-
quences of CDC42 mutations are required because these muta-
tions arise in a broad spectrum of clinical phenotypes.
Ultimately, it offers the possibility of designing specific thera-
peutic targeting of this pathway that is newly involved in auto-
inflammatory diseases.
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A novel STING1 variant causes a
recessive form of STING-associated
vasculopathy with onset in infancy
(SAVI)
To the Editor:
Stimulator of interferon response genes (STING) encoded by
stimulator of interferon response cGAMP interactor 1 (STING1),
previously known as transmembrane protein 173 (TMEM173) is
an important pattern recognition receptor that detects microbial
dinucleotides and functions as an adaptor molecule in the cyto-
solic DNA sensing pathway that binds 2’3’-cyclic GMP-AMP
(cGAMP), which is generated when cytosolic DNA activates
Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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cyclic GMP-AMP synthase (cGAS).1,2 STING activation stimu-
lates the induction of type I interferons, which activate interferon
responses. Gain-of-function (GOF) variants in STING1 lead to au-
toactivation without ligand binding and cause a rare autoinflam-
matory disease named STING-associated vasculopathy with
onset in infancy (SAVI) (Online Mendelian Inheritance in Man
catalog no. 615934).3,4 Patients with SAVI present in infancy
with the following symptoms: recurrent fevers; cold-induced
skin vasculitis that can progress to tissue loss and amputation of
fingers and toes; and/or interstitial lung disease, which is the
main cause of the mortality that often occurs before patients reach
adulthood. So far, all reported cases of SAVI have been caused
by autosomal dominant variants, with most of them occurring
de novo.
We have identified 6 patients from 4 unrelated families, all of
whom are of Arabic ethnicity and harbor pathogenic STING1
variants that are disease causing only in homozygosity. The
patients had clinical disease suggestive of SAVI andwere enrolled
into institutional review board–approved protocols, including the
National Institutes of Health natural history protocol
(NCT02974595).
Patient 1, the index patient, presented at 4 weeks of age with a
cough and failure to thrive, as well as with a maculopapular
violaceous rash with a livedoid appearance (Fig 1, A and B).
A chest computed tomography scan showed diffuse bilateral
parenchymal opacities. His lung disease progressed despite
steroid therapy and short-term treatment with the JAK inhibitor
tofacitinib, and he died of respiratory failure at 5 months of
age. His older brother (patient 2) died at 18 months of age with
chronic cough and failure to thrive. Although genetic testing
was not performed, the clinical manifestations and similarities
of patient 2 to those of his younger brother strongly suggest
that he had SAVI. Patient 3 presented at 3 months of age with
recurrent fever, erythematous rash, cough, and dyspnea,
ultimately progressing to oxygen dependence. He had a chest
computed tomography scan with results consistent with
interstitial lung disease and a lung biopsy specimen that showed
chronic interstitial pneumonitis with intraalveolar hemorrhage.
He is currently taking the JAK inhibitor ruxolitinib. His brother,
patient 4, had respiratory symptoms starting at the age of 6
months; he was diagnosed with SAVI at the age of 15 months
and was initially treated with steroids, after which baricitinib
(a selective JAK1/2 inhibitor) was added to his treatment regimen.
Patient 5 presented at the age of 2 months with cough, tachypnea,
and recurrent lung infections; she was diagnosed with chronic
aspiration pneumonia and had a laryngeal cleft that was repaired
at the age of 4.5 years. Because of her lung disease (Fig 1, E), she
has required supplemental oxygen since the age of 7 months and
bilevel positive airway pressure support while sleeping since the
second year of life, when digital clubbing was noticed. She
developed pulmonary hypertension by the age of 4 years. At the
age of 5 she developed polyarthritis, an erythematous rash over
the soles of her feet and clubbing. She began taking baricitinib
at the age of 7 years; there was clinical improvement, but her
oxygen dependence continued. Patient 6 presented at the age of
8 months with a history of persistent tachypnea and failure to
thrive, polyarthritis, intermittent vasculitic rashes, and clubbing
(Fig 1, C and D). All of the parents and siblings were
asymptomatic with normal inflammatory markers. Additional
clinical and laboratory information is available in Table E1
(in this article’s Online Repository at www.jacionline.org).
Patients 1, 3, and 4 underwent targeted sequencing of STING1,
whereas whole exome sequencing was performed on families 3
and 4. Sequencing of all patients revealed a homozygous STING1
(NM_198282) variant c.841C>T, p.Arg281Trp, p.R281W (Fig 1,
F). This variant was present in heterozygosity in only 2 of 282,822
alleles reported in gnomAD (gnomad.broadinstitute.org) and is
predicted to be damaging by PolyPhen-2 and deleterious by the
scale-invariant feature transform algorithm (SIFT), and it has a
Combined Annotation-Dependent Depletion (CADD)-PHRED-
scaled score of 26.4. This variant has not been reported previously
in patients with SAVI (https://infevers.umai-montpellier.fr). All of
the parents, as well as several of the unaffected siblings, were het-
erozygous carriers of this variant (Fig 1, F). Avariant affecting the
same amino acid residue but mutated to a glutamine (c.842G>A,
p.Arg281Gln, p.R281Q) has previously been described to cause
an autosomal dominant form of SAVI5 (Fig 1, G).
A strikingly high interferon response gene signature and
systemic inflammation in patients with SAVI has led to their
designation as having an autoinflammatory interferonopathy.6
A standardized interferon response gene score was elevated
only in patients who were homozygous for the p.R281W variant
and who had clinical disease, and not in the siblings and parents
who were heterozygous carriers of the variant or in healthy
controls (Fig 1, H).
Transfection ofHEK293T cells with the STING1 construct con-
taining the R281Wmutation led to activation of IFNB1 luciferase
reporter without ligand binding (see Fig E1 in this article’s Online
Repository at www.jacionline.org), indicating that p.R281W is a
pathogenic GOF variant. The mutant remained responsive to
cGAMP (see Fig E1), suggesting no effect on ligand binding.
Disease-causing SAVI variants3 cluster in 2 areas. The
cryoelectron microscopy structure model of STING7 has mapped
the class 1 variants, p.N154S, p.V155M, and p.V147L to the
connector helix loop (Fig 1, G) which controls a cGAMP
ligand–induced 180o rotation of the ligand-binding area of the
STING dimer that induces polymerization and activation. The
class 3 variants, including p.R281Q, p.R284G5 and p.R284S,8
are located at the polymerization interface7 (Fig 1, G) and have
been postulated to bind a C-terminal tail that might prevent
polymerization and autoactivation.9
Concordant with previous reports, we hypothesized that the
p.R281W variant confers a GOF that is weaker than the
heterozygous SAVI variants. To test this possibility, we
transfected HEK293T cells with either wild-type or mutant
STING constructs including R281Wat increasing concentrations
and assessed IFNB1 reporter activity (Fig 2, A). At equal
transfection efficiency, consistent with the homozygosity
requirement at this location, R281W mutant constructs exhibited
lower autoactivation than R281Q constructs did but were similar
to mutant constructs with the pathogenic V155M variant.
This suggests differential autoactivation thresholds for
disease-causing class 1 variants at the connector helix loop
(ie, V155M) versus class 3 variants at the polymer interface
(ie, R281 and R284). In line with this hypothesis, pathogenic
variants at the class 3 residues that cause disease in
heterozygosity, including R281Q, R284S, and R284G, are all
more autoactivating than V155M in the transfection model
(Fig 2, A and B), with R284S, R284G, and G158A constituting
the top 3 autoactivating SAVI variants (Fig 2, B).
Although class 1 disease-causing SAVI variants are GOF
variants, mutating these residues into charged amino acids
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(eg, V155R3 and G158E8) leads to loss of function, likely through
destabilizing the STING dimer structure. In contrast, none of the 6
different amino acid mutations at position R281 caused loss of
function (Fig 2, B [green labels]). In fact, all of the mutations
except for R281A, which is similar to the wild type, led to
autoactivation. Maintenance of a positive charge at residue
R281 (by mutating into lysine [K] or histidine [H]) was insuffi-
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FIG 1. Homozygous STING1 variant p.R281W causes SAVI. A-E, Clinical images showing typical cutaneous
features of vasculopathy for patient 1 (P1) (A and B) and P6 (C and D), as well as a chest computed
tomography scan (E) demonstrating reticulonodular densities throughout (P5). F, Family trees. G, Location
of p.R281W and other disease-causing SAVI mutations in the cryoelectron microscopy structure model of
STING. Highlighted are previously reported class 1 mutations in the connector helix loop, class 2 mutation
in the cGAMP binding pocket, and class 3 mutations on a surface-exposed region of STING dimer. H, Inter-
feron (IFN) scores of p.R281W homozygous patients and their parents compared with those of healthy
controls (HCs) or patients with neonatal-onset multisystem inflammatory disease (NOMID), chronic atypical
neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), or SAVI with
heterozygous GOF STING1 mutations. H, Heterozygous; M, homozygous; Std, standard; W, wild type.
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FIG 2. Multiple random STING1mutations at p.R281 lead to strong autoactivation.A, IFNB1 reporter activation
by R281W and other STING constructs transfected into HEK293T cells at increasing concentrations. B, R281
mutations led to strong STING autoactivation, as measured by IFNB1 reporter activation in HEK293T cells. In
particular, R281E was superactivating, comparable to the most activating mutation G158A in vitro. Quantities
of 50 pg of various STING constructs were transfected into 30,000 cells. cGAMP at various concentrations
was used to activate STING. SAVI-causing mutations are labeled in red, and other R281 mutations are labeled
in green. *An asterisk above the white bar designating 0 mg/mL of cGAMP indicates a significant change
(P < .0001) compared with the wild-type (WT) nontreated cells (indicated by the white bar), as determined by
the use of ordinary 1-way ANOVA (Dunnett multiple comparisons tests). An asterisk above the black bar
designating 20 mg/mL of cGAMP indicates a significant change (P < .003) of cells treated with 20 mg/mL of
cGAMP compared with the respective nontreated cells (indicated by the respective white bar), as determined
by the use of 2-way ANOVA (Bonferroni multiple comparisons tests). Data are presented as means 6 SDs of
duplicates. Similar results were obtained in independent experiments. C, A reconciled model to explain
autoactivation of polymer interface mutations. The 2 subunits of STING dimer are shown in yellow and green.
Polymer interfaces are indicated by red boxes. Inhibitors are shown as gray ellipses. The model assumes a
putative inhibitor that is bound to the polymer interface and is unable to bind in patients with disease-causing
mutation in either the connector helix loop region or in the polymer interface. For the full model and a detailed
description, see also Fig E3. EV, Empty vector; WT, wild-type. Modified with permission from Shang et al.E1
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mutations into hydrophobic amino acids such as tryptophan (W),
leucine (L), or methionine (M), or into negatively charged amino
acids (including glutamic acid [E]), cause autoactivation (Fig 2, A
and B). The autoactivation was not due to differential protein
expression in the transfection assay (see Fig E2 in this article’s
Online Repository at www.jacionline.org). The R281 and R284
mutations that were assessed remained responsive to cGAMP
stimulation (Fig 2, B and see Fig E1), indicating no effect on
ligand binding. The broad autoactivation of the R281 and R284
mutations was consistent with the model of polymer interface
binding to an inhibitor to suppress STING autoactivation.9
Although this potential inhibitor is not addressed in the 180o
rotation model of the connector helix loop mutations, it is quite
likely that the 180o rotation also leads to loss of inhibitor binding
on the polymer interface, thus allowing side-by-side packing. Our
data thus suggest a possible common mechanism to reconcile the
2 previously reported structural models (Fig 2, C and see also the
Discussion section for detailed description of the model shown in
Fig E3 in this article’s Online Repository at www.jacionline.org),
which is supported by similar superactivating mutations in both
the connector helix loop (G158A) and the polymer interface
(R281E, R284G, and R284S).
In summary, we have reported 6 patients from 4 unrelated
families with recessively inherited STING1 variants and charac-
teristic clinical features of SAVI. Our data support the notion
that the disease-causing homozygous p.R281W variant causes
GOF but is weaker in activating STING than the previously re-
ported heterozygous variants, and it requires biallelic mutations
to constitutively activate STING.We have demonstrated a critical
role of residue R281 in maintaining STING in an inactive state,
likely without affecting dimer conformation. Our data unveil lim-
itations of the current structural models that cannot explain the
superactivating potential of the R281 and R284 mutations and
raise questions as to whether class 3 residues represent an autoin-
hibitory domain or a binding site for an external inhibitor of
STING. Considering the critical function of R281 and the nearby
region, novel therapeutic options may arise from high-throughput
screens of drugs that bind to this area and inhibit polymerization.
We thank the patients and their families for participating in this study.
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A rare case of selective Igk chain
deficiency: Biologic and clinical
implications
To the Editor:
Selective Igk and Igl deficiencies are extremely rare. So far,
there have been few reported cases of Igk deficiency in the
English literature, and all but 2 of them are partial in nature.1-3
The first reported case of complete Igk deficiency was that of a
male patient with concurrent cystic fibrosis, diabetes mellitus,
malabsorption, and IgA deficiency4; notably, 1 of the patient’s sis-
ters had only trace amounts of k1 immunoglobulins. Sequencing
of the k constant region (IGKC) in this patient identified a
different single-point mutation in each allele, p.Trp41Arg and
p.Cys87Gly, each of which would disrupt stable k chain folding.5
The second published case was that of a 62-year-old female from
southern Italy who had a history of recurrent respiratory infec-
tions and intestinal disorders from early childhood andwas homo-
zygous for the p.Cys87Gly point mutation observed in the
original patient.6
Our patient is a 73-year-old white female; she is a retired nurse
who has peripheral neuropathy but is otherwise healthy and with
no history of immunodeficiency; nor is there any recorded history
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METHODS
Patients
All patients were enrolled into the institutional review board–approved
National Institutes of Health natural history protocol Studies of the Natural
History, Pathogenesis, and Outcome of Autoinflammatory Diseases
(NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still’s-like
Diseases, and Other Undifferentiated Autoinflammatory Diseases)
(17-I-0016; NCT02974595). Parents gave written informed consent for their
children in accordance with the Declaration of Helsinki.
IFNB1 luciferase reporter assay
HEK293T cells were cotransfected with STING constructs and an IFNB1
firefly luciferase reporter construct with Lipofectamine 3000 reagent
(ThermoFisher Scientific, Waltham, Mass; catalog no. L3000015) in
96-well plates (black wall with clear bottom [BD Falcon, Frankin Lakes,
NJ; catalog no. 353219]) with a reverse transfection protocol. Briefly, for 1
well of 96-well plate, 0.5 mL of IFNB1 firefly luciferase reporter construct
(100 ng/mL) was mixed with 5 mL of Opti-MEM, 0.2 mL of P300 reagent,
and various amounts of STING constructs (6.25-400 pg in a volume of
0.25-0.4mL), as indicated. The vector dilutions were then mixed with the Lip-
ofectamine 3000 dilutions containing 5 mL of Opti-MEM and 0.3 mL of Lip-
ofectamine 3000 and subsequently incubated at room temperature for 10 to 30
minutes. During the incubation period, HEK293T cells were harvested by
trypsin digestion and diluted in complete Dulbecco modified Eagle medium
to a density of 400,000 cells/mL. The transfectionmix was applied to thewells
following the incubation, after which 75mL of diluted HEK293T cells (30,000
cells) was added to each well. To mix, the plate was gently tapped and then
rocked back and forth to allow even distribution of the cells, followed by 10
minutes of incubation at room temperature to allow the cells to settle. The
plates were then returned to 378C in a humidified atmosphere with 5% CO2
for 24 hours. The luciferase assay was carried out by using the ONE-Glo
EX Luciferase Assay System (Promega, Madison, Wis; catalog no. E8120),
with 50 mL of luciferase reagent per well.
cGAMP stimulation
For cGAMP stimulation, 1.8 mL of cGAMP (1 mg/mL) was diluted with
3.2 mL of complete Dulbecco modified Eagle medium and added to 1 well
(of a 96-well plate) containing 85 mL of cultured HEK 293 T cells at 6 hours
after transfection for a final concentration of 20 mg/mL.
Western blot
Transfectionwas carried out as already described except that 24-well plates
were used (Corning Costar, Corning, NY; catalog no. 3524) and reagents and
cells were added in quantities 4 times larger than in the 96-well plate. Briefly,
800 pg of STING construct and 200 ng of IFNB1 firefly luciferase reporter
construct were cotransfected into 120,000 HEK293T cells in each well.
Cells were harvested at 24 hours after transfection and were first washed
with 1 mL of PBS, after which 50 mL of complete radioimmunoprecipitation
assay (RIPA) buffer (composed of 9 mL of distilled water and 1 mL of 103
RIPA buffer [Cell Signaling Technology, Danvers, Mass; catalog no. 9086]; 1
tablet of cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail [Roche
Applied Science, Penzberg, Germany; catalog no. 11836170001]; 1 tablet of
PhosSTOP phosphatase inhibitor [Roche Applied Science, catalog no.
4906837001]; and 0.125 g ofN-ethylmaleimide [Sigma, St Louis,Mo; catalog
no. E3876]) was added. The mixture was placed on ice for 10 minutes to lyse
the cells. The lysatewas collected into a 1.5-mL tube, vortexed for 15 seconds,
and then spun at 17,000 g at 48C for 10 minutes. The supernatant was trans-
ferred to a new tube. Protein concentrations weremeasured by using a DC pro-
tein assay kit (BIO-RAD, Hercules, Calif; catalog no. 5000116) with BSA as a
standard. All samples were diluted to the same concentration with complete
RIPA buffer, then mixed with NuPAGE Sample Reducing Agent (10X) (Invi-
trogen, Carlsbad, Calif; catalog no. NP0004) and XT Sample Buffer (4X)
(BIO-RAD, catalog no. 1610791), and then heated at 708C for 10 minutes.
For each sample, 12mg of protein was loaded in 10%Criterion XTBis-Tris
Protein Gel (BIO-RAD, catalog no. 3450112) and electrophoresis was carried
out in 3-(N-morpholino)propanesulfonic acid buffer (BIO-RAD, catalog
no.1610793) by using Criterion Cell (BIO-RAD, catalog no. 1656001) at
200 V constant voltage for about 60 minutes. Next, 150 mL of NuPAGE
Antioxidant (Invitrogen, catalog no. NP0005) was applied to the upper
chamber buffer before the electrophoresis.
The proteins were transferred to polyvinylidene difluoride membranes
(Trans-Blot Turbo Midi PVDF Transfer Packs, BIO-RAD, catalog no.
1704157) with the Trans-Blot Turbo Transfer System (BIO-RAD, catalog
no.1704150) under the preprogrammed protocol for OneMidi Format gel with
a mixed molecular weight (2.5 A and <_25 V for 7 minutes). The blots were
then incubated and washed with gentle agitation (50 rpm) with Labnet Orbit
low speed lab shaker (Labnet International, Edison, NJ; catalog no. S2030-LS-
B) as detailed here. First, the blots were incubated in 20 mL of blocking buffer
(5% nonfat dry milk, 13 Tris-buffered saline [TBS], and 0.1% Tween-20) at
room temperature for 1 hour. Then they were washed for 5 minutes 3 times
with about 20 mL of washing buffer (13 TBS and 0.1% Tween-20); followed
by incubation in 0.2 mg/mL of anti-STING antibody (R&D Systems,
Minneapolis, Minn; catalog no. MAB7169-SP) diluted in 12 mL of primary
antibody dilution buffer (5% BSA, 13 TBS, and 0.1% Tween-20) at 48C
overnight with gentle agitation. The blot was then washed with washing buffer
for 10 minutes 3 times, followed by 1 hour of incubation at room temperature
in 12 mL of blocking buffer containing 6 mL of secondary antibody
(Amersham ECL Sheep anti-Mouse IgG, Horseradish Peroxidase–Linked
Whole Antibody, catalog no. NA931-1ML) and 12 mL of hFAB rhodamine
anti-actin primary antibody (BIO-RAD, catalog no. 12004163). To remove
any unbound antibodies, the membranes were washed for 10 minutes 3 times,
after which SuperSignal West Dura Extended Duration Substrate (Thermo-
Fisher Scientific, catalog no. 34076) was applied. Images for STING1 and
ACTB were captured with BIO-RAD ChemiDoc.
DISCUSSION
STING detects microbial dinucleotides and functions as an
adaptor molecule in the cytosolic DNA-sensing pathway that
binds cGAMP, which is generated when cytosolic DNA activates
cyclic cGAS.E2-E6 The observed GOF of the STING autoactivat-
ing and disease-causing mutations was recently ‘‘explained’’ on
the basis of 2 structural models.E1,E7 The cryoelectron micro-
scopy structure model suggests that cGAMP binding to the
STING dimer causes a 1808 rotation of the ligand-binding domain
along a connector helix loop. This flattens the polymerization in-
terfaces and enables side-by-side packing of STING dimers into
polymersE1 that serve as a platform for TBK1 cross-phosphoryla-
tion and subsequent signaling activation.E8 Mutations of residues
in the connector helix loop are referred to as class 1 SAVI muta-
tions and include p.N154S and p.V155M (see Fig 1,G in the print
text). These mutations favor a remodeling of the STING dimer
structure into an autoactivated conformation. This model, howev-
er, cannot explain the mechanism of autoactivation of class 3 mu-
tations in the polymer interface, including p.R281Q, p.R284G,
and p.R284S, which are not predicted to induce remodeling of
the STING dimer.
Another structural model proposes that residues in the polymer
interface bind a C-terminal tail, which blocks STING polymer-
ization.E7 The class 3 SAVI mutations might therefore lose the
ability to bind the C-terminal tail or an inhibitor (the latter is
shown in the model) and cause autoactivation. Despite the differ-
ences between the 2 models, both converge at a conformational
change in the polymer interface and STING activation.
Our data in fact suggest a possible common mechanism to
reconcile the 2 previously reported structural models. The broad
autoactivation of R281 and R284mutations strongly suggests that
the polymer interface binds to an inhibitor to suppress STING
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autoactivation. On the basis of this reasoning, cGAMP binding to
STING may not simply ‘‘flatten’’ the polymer interface but may
also lead to loss of inhibitor binding capability as a result of the
structural change in the polymerization interface (in the top panel
Fig E3,E1-E7 the inhibitors [which bind to the 2 dimer subunits on
the front and back, respectively] are shown in black). This allows
180o rotation and STING polymerization. Similarly, STING di-
mers with class 1 mutations mimic the cGAMP-bound STING
structure and lost inhibitor binding, which leads to activation
(in the middle panel of Fig E3, the location of connector helix
loop is indicated by a red box).
Our hypothetical model likely explains the higher autoactiva-
tion threshold for class 3 mutations than for class 1 mutations. On
the basis of the current structural model, V155 is located in the
closely packed dimer interface, and mutations into a methionine
(M) change the molecular interactions inside the dimer, favoring
an active dimer conformation.E1 This conformational change can
even happen in the wild-type/mutant heterodimers, which is sup-
ported by the fact that V155M mutations are disease causing in
heterozygosity and show a lower autoactivation threshold than
class 3 mutations, including R281Q, R284S, and R284G (see
also Fig 2, A and B). In contrast, for class 3 mutations in the
polymer interface (indicated by a red box in the bottom panel
of Fig E3), only the mutant-mutant homodimers are able to fully
resolve the inhibitor blocking on both sides of the STING dimer
(Fig E3, bottom panel). Consistent with this hypothesis, the class
3 mutations either require homozygosity to be disease causing
(eg, p.R281W) or they need to be superautoactivating to cause
SAVI in heterozygosity (eg, R281Q, R284S, and R284G). Further
structural studies of the class 3 superautoactivating mutations are
required to test this hypothesis and enhance our understanding of
STING activation. Considering the reports of the STINGC-termi-
nal tail functioning as an autoinhibitory suppressorE7 and discov-
eries of other STING binding partners, including TOLLIP,
IRE1a,E9 and STIM1,E10 it remains to be determined whether
these STING-binding proteins/domains represent various STING
inhibitors or form a single suppressor complex.
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FIG E1. The R281W mutant is autoactivating and remains responsive to
cGAMP stimulation. Quantities of 50 pg of various STING constructs were
transfected into 30,000 HEK293T cells and stimulated with cGAMP at 6
hours after transfection. ****P < .0001 by 2-way ANOVA and the Dunnett
multiple comparison test. WT, Wild-type.
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FIG E2. Protein expression of transfected constructs in HEK293T cells by
Western blot. STING1-expressing constructs (800 pg) were transfected into
120,000 HEK293T cells, and STING1 and ACTB were detected in
chemiluminescent and rhodamine channels, respectively, in the same blot.
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FIG E3. Proposed disease models for class 1 and class 3 mutations. The 2 subunits of the STING dimer are
shown in yellow and green. Sites of SAVI-causingmutation are indicated by red boxes. Inhibitors are shown
as a gray ellipse. The model assumes that a putative inhibitor is bound to the polymer interface of the wild-
type STING dimer, which blocks the polymer formation. cGAMP-binding to the binding domain of STING
(top panel) or mutations in the connector region (middle panel) cause a 1808 rotation of the ligand-binding
domain along the connector helix loop, which leads to the release of the inhibitor. This allows polymer for-
mation via side-by-side packing and STING activation. Mutations in the polymer interface (bottom panel)
directly lead to inability of inhibitor binding, which causes STING autoactivation. WT, Wild-type. Modified
with permission from Shang et al.E1
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1 4 wk Syrian Yes Yes Diffuse bilateral
parenchymal opacities




2 Unknown Syrian Unknown Yes ND Unknown Unknown Unknown Died at age
18 mo









Elevated CRP level; ESR;

































Elevated CRP level, ESR,





6 8 mo Syrian Yes Yes Cystic lesions, RUL
fibrosis
Polyarthritis, clubbing,




Elevated CRP level, ESR,







ANA, Antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; anti-PR3, anti-proteinase 3 antibody; c-ANCA, cytoplasmic antineutrophil cytoplasmic antibody; CRP, C-reactive protein; CT, computed tomography;
dsDNA, double-stranded DNA; ESR, erythrocyte sedimentation rate; GERD, gastroesophageal reflux disease; MPO, myeloperoxidase; ND, not done; RUL, right upper lobe.
*Patient 5 had a heterozygous mutation in ADA2/CECR1, but with normal enzymatic levels.
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